{"title":"芳烃受体(AHR)配体6-甲酰基林多洛[3,2-b]卡唑(FICZ)在大鼠体内的药代动力学和组织分布:对AHR激活和细胞色素P450酶活性的影响","authors":"Neda Hajizadeh, Fereshteh Asadi Dolatabad, Najmeh Ekhtiyardar, Fatemeh Ahmadi, Afshin Mohammadi Bardbori","doi":"10.1186/s43094-025-00889-1","DOIUrl":null,"url":null,"abstract":"<div><p>The aryl hydrocarbon receptor (AHR) ligand, 6-formylindolo[3,2-b]carbazole (FICZ), plays a pivotal role in modulating various biological processes, including circadian rhythms and maintenance of cellular homeostasis. This study aimed to investigate the pharmacokinetics, tissue distribution, and metabolic clearance of FICZ in vivo using high-performance liquid chromatography (HPLC) with fluorescence detection and an ethoxyresorufin-O-deethylase (EROD) assay. FICZ was administered intraperitoneally to rats in varying doses (42.6 µg/kg, 85.2 µg/kg, 127.9 µg/kg, and 426.4 µg/kg) at multiple time points (1, 3, and 6 h). The liver was identified as the primary organ for FICZ distribution, with peak concentrations observed at 1 h, whereas metabolism by cytochrome P450 enzymes, particularly CYP1A1, led to a significant reduction in FICZ levels over time. Additionally, heart, testis, and brain tissues exhibited varying FICZ accumulation patterns, with dose-dependent distribution observed in testes. The findings highlight the tissue-specific pharmacokinetics of FICZ, with its distribution influenced by both dose and exposure time. EROD activity, a marker for CYP1A1 induction, peaked at 3-h post-administration and was inversely correlated with FICZ degradation. The rapid metabolism of FICZ, exacerbated by its susceptibility to photodegradation, complicates the detection and quantification of endogenous FICZ in vivo. This study presents the first comprehensive assessment of FICZ pharmacokinetics and tissue distribution in various rat tissues, including the liver, heart, brain, prostate, and testis, while also exploring its link to CYP1A1 modulation. This study underscores the complexity of FICZ’s pharmacokinetic, suggesting that both dose- and tissue-specific responses play crucial roles in AHR activation and subsequent enzyme activity. These results contribute to a deeper understanding of FICZ’s biological effects, offering insights into its therapeutic potential and toxicological implication.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00889-1","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics and tissue distribution of the aryl hydrocarbon receptor (AHR) ligand, 6-formylindolo[3,2-b]carbazole (FICZ) in rat: implications for AHR activation and Cytochrome P450 enzyme activity\",\"authors\":\"Neda Hajizadeh, Fereshteh Asadi Dolatabad, Najmeh Ekhtiyardar, Fatemeh Ahmadi, Afshin Mohammadi Bardbori\",\"doi\":\"10.1186/s43094-025-00889-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The aryl hydrocarbon receptor (AHR) ligand, 6-formylindolo[3,2-b]carbazole (FICZ), plays a pivotal role in modulating various biological processes, including circadian rhythms and maintenance of cellular homeostasis. This study aimed to investigate the pharmacokinetics, tissue distribution, and metabolic clearance of FICZ in vivo using high-performance liquid chromatography (HPLC) with fluorescence detection and an ethoxyresorufin-O-deethylase (EROD) assay. FICZ was administered intraperitoneally to rats in varying doses (42.6 µg/kg, 85.2 µg/kg, 127.9 µg/kg, and 426.4 µg/kg) at multiple time points (1, 3, and 6 h). The liver was identified as the primary organ for FICZ distribution, with peak concentrations observed at 1 h, whereas metabolism by cytochrome P450 enzymes, particularly CYP1A1, led to a significant reduction in FICZ levels over time. Additionally, heart, testis, and brain tissues exhibited varying FICZ accumulation patterns, with dose-dependent distribution observed in testes. The findings highlight the tissue-specific pharmacokinetics of FICZ, with its distribution influenced by both dose and exposure time. EROD activity, a marker for CYP1A1 induction, peaked at 3-h post-administration and was inversely correlated with FICZ degradation. The rapid metabolism of FICZ, exacerbated by its susceptibility to photodegradation, complicates the detection and quantification of endogenous FICZ in vivo. This study presents the first comprehensive assessment of FICZ pharmacokinetics and tissue distribution in various rat tissues, including the liver, heart, brain, prostate, and testis, while also exploring its link to CYP1A1 modulation. This study underscores the complexity of FICZ’s pharmacokinetic, suggesting that both dose- and tissue-specific responses play crucial roles in AHR activation and subsequent enzyme activity. These results contribute to a deeper understanding of FICZ’s biological effects, offering insights into its therapeutic potential and toxicological implication.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00889-1\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00889-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00889-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
芳烃受体(AHR)配体6-甲酰基林多洛[3,2-b]咔唑(FICZ)在调节昼夜节律和维持细胞稳态等多种生物过程中起着关键作用。本研究旨在利用荧光检测的高效液相色谱(HPLC)和乙氧基间苯二酚- o -去乙基酶(EROD)测定法研究FICZ在体内的药代动力学、组织分布和代谢清除率。FICZ以不同剂量(42.6µg/kg、85.2µg/kg、127.9µg/kg和426.4µg/kg)在多个时间点(1,3和6 h)腹腔注射给鼠。肝脏被确定为FICZ分布的主要器官,在1 h时观察到峰值浓度,而细胞色素P450酶的代谢,特别是CYP1A1,导致FICZ水平随着时间的推移显着降低。此外,心脏、睾丸和脑组织表现出不同的FICZ积累模式,并在睾丸中观察到剂量依赖性分布。研究结果强调了FICZ的组织特异性药代动力学,其分布受剂量和暴露时间的影响。EROD活性是CYP1A1诱导的标志,在给药后3小时达到峰值,与FICZ降解呈负相关。由于FICZ对光降解的敏感性加剧了其快速代谢,使得体内内源性FICZ的检测和定量复杂化。本研究首次全面评估了FICZ在各种大鼠组织中的药代动力学和组织分布,包括肝脏、心脏、大脑、前列腺和睾丸,同时也探索了其与CYP1A1调节的联系。这项研究强调了FICZ药代动力学的复杂性,表明剂量特异性和组织特异性反应在AHR激活和随后的酶活性中起着至关重要的作用。这些结果有助于更深入地了解FICZ的生物学效应,为其治疗潜力和毒理学意义提供见解。
Pharmacokinetics and tissue distribution of the aryl hydrocarbon receptor (AHR) ligand, 6-formylindolo[3,2-b]carbazole (FICZ) in rat: implications for AHR activation and Cytochrome P450 enzyme activity
The aryl hydrocarbon receptor (AHR) ligand, 6-formylindolo[3,2-b]carbazole (FICZ), plays a pivotal role in modulating various biological processes, including circadian rhythms and maintenance of cellular homeostasis. This study aimed to investigate the pharmacokinetics, tissue distribution, and metabolic clearance of FICZ in vivo using high-performance liquid chromatography (HPLC) with fluorescence detection and an ethoxyresorufin-O-deethylase (EROD) assay. FICZ was administered intraperitoneally to rats in varying doses (42.6 µg/kg, 85.2 µg/kg, 127.9 µg/kg, and 426.4 µg/kg) at multiple time points (1, 3, and 6 h). The liver was identified as the primary organ for FICZ distribution, with peak concentrations observed at 1 h, whereas metabolism by cytochrome P450 enzymes, particularly CYP1A1, led to a significant reduction in FICZ levels over time. Additionally, heart, testis, and brain tissues exhibited varying FICZ accumulation patterns, with dose-dependent distribution observed in testes. The findings highlight the tissue-specific pharmacokinetics of FICZ, with its distribution influenced by both dose and exposure time. EROD activity, a marker for CYP1A1 induction, peaked at 3-h post-administration and was inversely correlated with FICZ degradation. The rapid metabolism of FICZ, exacerbated by its susceptibility to photodegradation, complicates the detection and quantification of endogenous FICZ in vivo. This study presents the first comprehensive assessment of FICZ pharmacokinetics and tissue distribution in various rat tissues, including the liver, heart, brain, prostate, and testis, while also exploring its link to CYP1A1 modulation. This study underscores the complexity of FICZ’s pharmacokinetic, suggesting that both dose- and tissue-specific responses play crucial roles in AHR activation and subsequent enzyme activity. These results contribute to a deeper understanding of FICZ’s biological effects, offering insights into its therapeutic potential and toxicological implication.
期刊介绍:
Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.